ArticleBulletin of experimental biology and medicine2022
Rapamycin Enhanced Sensitivity of HT-29 Cells to 5-Fluororacil by Promoting Autophagy.
Article in Bulletin of experimental biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diet-dependent, beneficial and adverse effects of rapamycin on life span of Drosophila melanogaster.GeroScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the effect of cytostatic rapamycin on the antitumor activity of 5-fluorouracil (5-FU). To this end, HT-29 cells were treated with 5-FU, or rapamycin, or their combination. The proliferation and apoptosis of treated cells were evaluated using Cell Counting Kit-8 kit and flow cytometry, respectively. The autophagy was evaluated by transmission electron microscopy and Western blotting by the expression of p62, LC3I, and LC3II proteins. 5-FU inhibited proliferation and promoted apoptosis of HT-29 cells, and the combination of 5-FU with rapamycin potentiated both effects. Rapamycin promoted accumulation of autophagosome/autolysosome and enhanced the level of LC3II/LC3I. Thus, rapamycin enhances the antitumor activity of 5-FU by stimulating autophagy and increasing LC3II/LC3I. The results confirm a potential therapeutic strategy for the clinical application of 5-FU.
Indexed as
Identifiers
36063298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.